Irm LLC

Novartis Ag

Novartis Pharma Gmbh

Wenqi Gao

Shifeng Pan

Dai Cheng

Dong Han

Nathanael Schiander Gray

Yuan Mi

Guobao Zhang

Yi Fan

Yongqin Wan

Jiqing Jiang

Tao Jiang

Yun Feng Xie

Yun He

Lawrence Blas Perez

Yongping Xie

Nathanael S Gray

Peter Ettmayer

Klaus Hinterding

Wenshuo Lu

Peter Nussbaumer

Xu Wu

Yahua Liu

Qihui Jin

Wei Wang

Thomas Marsilje

Rajender Reddy Leleti

Sophie Lefebvre

Lichun Shen

Ying Fan

Frédéric Zecri

Kenneth Richard La Montagne

The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), 

N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators

The present invention relates to compositions and methods for modulating the Wnt signaling pathway.

N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).

Hedgehog pathway modulators

The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R, R, Rare as defined herein. 

Substituted pyridines for modulating the WNT signaling pathway

The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A, A, B, Y and Z all represent rings. 

N-(hetero)aryl, 2-(hetero)aryl&#x2014;substituted acetamides for use as Wnt signaling modulators

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I). 

Compounds and compositions as hedgehog pathway inhibitors

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

Compounds and compositions as hedgehog pathway modulators

The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

Immunosuppresant compounds and compositions

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I. 

Compounds and compositions as hedgehog signaling pathway modulators

Immunosuppressant compounds and compositions

The invention provides a novel class of cyclic oximes of Formula I: wherein A, X, Y, Z, W, R, R, Rand n are as described in the summary of the invention; useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

The present invention relates to bicyclic derivatives, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG/S1P receptor mediated signal transduction.

Bicyclic compounds and compositions

Growing community of inventors

San Diego, CA, United States of America

Wenqi Gao